Spots Global Cancer Trial Database for A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Official Title: A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Study ID: NCT02713984
Interventions
Study Description
Brief Summary: Chimeric antigen receptor T cells (CAR-T) therapy has not yet been fully explored in solid tumors. Human epidermal growth factor receptor-2(HER2) is widely expressed in cancers. Investigators have developed anti-HER2 CAR-modified T cells and validated the efficiency targeting HER2-positive cancer in preclinical studies. This study is aimed to confirm its adverse effects including cytokine storm response and any other adverse effects. In addition, CAR-T cells persistence, tumor elimination and disease status after treatment will be evaluated.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China
Contact Details
Name: Cheng Qian, MD,PhD
Affiliation: Southwest Hospital, China
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
